Analyst Tim Anderson of Bank of America Securities reiterated a Buy rating on Metsera, Inc., boosting the price target to $45.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Tim Anderson has given his Buy rating due to a combination of factors including the recent positive clinical data and the strategic positioning of Metsera, Inc. The company presented promising early data at the American Diabetes Association annual meeting for its amylin agonist, MET-233i, which has partially de-risked the program and led to an increased price objective. This development, along with the competitive landscape for amylin agonists, supports a favorable outlook for MTSR.
Additionally, Metsera, Inc. is poised for multiple catalysts over the next 12 months, with significant readouts expected from various clinical trials. These include data from MET-097i and MET-233i programs, which are expected to provide further insights into their efficacy in treating obesity. The company’s strong position in the obesity space, with a diverse portfolio of wholly-owned compounds and a scalable cost structure, further justifies the Buy rating.
According to TipRanks, Anderson is a 4-star analyst with an average return of 10.9% and a 63.16% success rate. Anderson covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Gilead Sciences, and Amgen.